BioWorld

Sep. 10, 2004

SGX, Roche Partner To Use FAST To Discover Antivirals

Entering the first major pharmaceutical deal for its Fragments of Active Structures drug discovery technology, Structural GenomiX formed an alliance with F. Hoffmann-La Roche Ltd. to discover new antiviral therapeutics. (BioWorld Today) Read More

InKine, FDA Agree On SPA For INKP-102 Phase III Trial

Transcytosis Research Lending Hope In Long Fight Against HIV

Push For Public Posting Of Clinical Trial Data Continues

Graffinity Closes Merger With MyoContract, Forms Santhera

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 6, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 6, 2025.

DNA mutations or genetic disorder concept art

Regenxbio’s Duchenne gene therapy data positive as shares falter

BioWorld

Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...

EMA warns Ozempic linked to ‘very rare’ side effect

BioWorld

The EMA’s safety committee has issued a warning that the GLP-1 receptor agonist Ozempic (semaglutide, Novo Nordisk A/S) can cause an acute eye condition in which...

Aiatella secures €2M for AI-based cardiovascular imaging tech

BioWorld MedTech

Aiatella Oy secured €2 million (US$2.28 million) in funding for its AI-powered cardiovascular imaging technology. The funds will be used to conduct clinical...